What are the clinical benefits and potential disadvantages of switching from fedratinib to momelotinib in the management of myelofibrosis?
Fuente:
Zenodo
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Recurso digital |
| Publié: |
Zenodo
2026
|
| Sujets: | |
| Accès en ligne: | |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1866901566085136384 |
|---|---|
| author | Tripdatabase |
| author_facet | Tripdatabase |
| contents | Switching from fedratinib to momelotinib in myelofibrosis management may enhance anemia control and symptom relief, though it carries potential disadvantages such as side effects and cost. Direct comparisons between these drugs are needed to better understand their relative benefits and risks. |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_19242464 |
| institution | Zenodo |
| language | |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | What are the clinical benefits and potential disadvantages of switching from fedratinib to momelotinib in the management of myelofibrosis? Tripdatabase myelofibrosis fedratinib momelotinib clinical benefits treatment switch haematology pharmacology long-term management treatment disadvantages Switching from fedratinib to momelotinib in myelofibrosis management may enhance anemia control and symptom relief, though it carries potential disadvantages such as side effects and cost. Direct comparisons between these drugs are needed to better understand their relative benefits and risks. |
| title | What are the clinical benefits and potential disadvantages of switching from fedratinib to momelotinib in the management of myelofibrosis? |
| topic | myelofibrosis fedratinib momelotinib clinical benefits treatment switch haematology pharmacology long-term management treatment disadvantages |
| url | https://doi.org/10.5281/zenodo.19242464 |